PLoS pathogens · 2022
Unique cellular immune signatures of multisystem inflammatory syndrome in children.
СтатьяResearch Support, N.I.H., IntramuralНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rajamanickam Anuradha, Nathella Pavan Kumar, Venkataraman Aishwarya, Varadarjan Poovazhagi, Kannan Srinithi, Pandiarajan Arul Nancy, Renji Rachel Mariam, Elavarasan Elayarani, Thimmaiah Akshith, Sasidaran Kandasamy, Krishnamoorthy Nedunchelian, Natarajan Suresh, Ramaswamy Ganesh, Sundaram Balasubramanian, Putlibai Sulochana, Hissar Syed, Selladurai Elilarasi, Uma Devi K Ranganathan, Nutman Thomas B, Babu Subash
Аннотация
The clinical presentation of MIS-C overlaps with other infectious/non-infectious diseases such as acute COVID-19, Kawasaki disease, acute dengue, enteric fever, and systemic lupus erythematosus. We examined the ex-vivo cellular parameters with the aim of distinguishing MIS-C from other syndromes with overlapping clinical presentations. MIS-C children differed from children with non-MIS-C conditions by having increased numbers of naïve CD8+ T cells, naïve, immature and atypical memory B cells and diminished numbers of transitional memory, stem cell memory, central and effector memory CD4+ and CD8+ T cells, classical, activated memory B and plasma cells and monocyte (intermediate and non-classical) and dendritic cell (plasmacytoid and myeloid) subsets. All of the above alterations were significantly reversed at 6-9 months post-recovery in MIS-C. Thus, MIS-C is characterized by a distinct cellular signature that distinguishes it from other syndromes with overlapping clinical presentations. Trial Registration: ClinicalTrials.gov clinicaltrial.gov. No: NCT04844242.